Shanghai Pharmaceuticals (02607.HK): Sulfate salbutamol injection passes generic drug consistency evaluation.

China Finance and Economics App News, Shanghai Pharmaceuticals (02607.HK) announced that recently, Shanghai Pharmaceuticals Group Co., Ltd. (hereinafter referred to as the "Company") announced that its subsidiary Shanghai Hefeng Pharmaceutical Co., Ltd. (hereinafter referred to as "Hefeng Pharmaceuticals") has received the "Drug Supplementary Application Approval Notice" (Notice No.: 2025B03280) issued by the National Medical Products Administration (hereinafter referred to as the "NMPA") for its Albuterol Sulfate Injection (hereinafter referred to as the "drug"), indicating that the drug has passed the generic drug quality and efficacy consistency evaluation.